Affiliation:
1. St. Petersburg State University of Veterinary Medicine
Abstract
The state of reproductive health of females determines not only their successful insemination, but also the birth of healthy viable young. However, in the conditions of livestock complexes, one often has to deal with pathologies of the reproductive tract organs, among which, recently, diseases characterized by a long latent period have become most relevant, which complicates their timely diagnosis and therapy. One of these diseases is genital mycoplasmosis of cattle. The aim of our research was to study the therapeutic efficacy of the antibiotic tulatromycin in genital mycoplasmosis in cows and its effect on the immunobiological properties of vaginal secretions. For the experiment, two groups of cows were formed, 8 heads each. The first group (experimental) – cows with a positive PCR test for Mycoplasma spp., who were treated with the antibiotic traksovet (tulatromycin) subcutaneously, at the rate of 2.5 mg per 1 kg of animal body weight, once. The second group (control) – clinically healthy cows with a negative PCR test for Mycoplasma spp. In animals, a secret was collected from the vaginal walls in which the concentration of hydrogen ions (pH), lysozyme activity, Ig G, Ig M, Ig A and sIg A content were determined. Therapeutic efficacy was evaluated by repeated PCR test 14 days after the drug application. The use of tulatromycin in a dose of 2.5 mg per 1 kg of animal body weight for the treatment of cows with genital mycoplasmosis, once leads to the elimination of the pathogen from the genital tract in 75% of sick animals, which indicates its high therapeutic efficacy. In addition, tulatromycin therapy leads to a partial normalization of the vaginal secretion reaction and its lysozyme activity, but they do not reach the level of healthy cows. The content of immunoglobulin classes in vaginal secretions under the action of the drug underwent recovery to their levels in healthy animals.
Publisher
Saint-Petersburg State University of Veterinary Medicine
Reference8 articles.
1. Alhussen A. M. Pathogenic mycoplasmas of cattle mycoplasma bovis, m. bovigenitalium and m. dispar: a brief description of pathogens / A.M. Alhussen, V.V. Kirpichenko, S.P. Yatsentyuk and others // Agricultural biology, 2021. - Volume 56, No. 2. - S. 245-260.
2. Vasiliev R.M. Immuno-biochemical status of cows with genital mycoplasmosis /R.M. Vasiliev // Legal regulation in veterinary medicine, 2022. - No. 1. - P. 35-37.
3. Voinova A.A. Assessment of the prevalence of hepatosis among cows of dairy herds /A.A. Voinova, S.P. Kovalev, G.S. Nikitin // Proceedings of the international scientific conference of the faculty, researchers and postgraduate students of SPbGAVM. St. Petersburg:, 2017. - S. 16-17.
4. Karpov O.I. Macrolides: a new paradigm: pharmacodynamics immunomodulation /O.I. Karpov // Clinical. pharmacology and therapy. - 2005. - Volume 14, No. 5. - S. 20-30.
5. Cooper A.C. In vitro activity of danofloxacin, tylosin and oxytetracycline against mycoplasmas of veterinary importance /A.C. Cooper, J.R. Fuller, M.K. Fuller, P. Whittlestone, D.R. Wise// Research in Veterinary Science. – 1993. – Vol. 54, Issue 3. – Р. 329-334.